STATegics, Inc. is structured around discovery and development of breakthrough new treatments for life-threatening rare neurodegenerative diseases. The firm is developing small molecule agonists of the tissue-protective receptor for treatment of CNS and rare diseases, including Friedreichâs ataxia and Parkinsonâs disease, with potential for additional opportunities in Alzheimerâs disease, ALS, multiple sclerosis, schizophrenia, depresion and peripheral neuropathy. By targeting the tissue-protective cytokine receptor, STATegics has identified novel small molecules to address the underlying cause of Friedreichâs ataxia (FA), a rare neuromuscular disease for which no treatment is available. In addition to addressing critical drivers in FA, STATegicsâ molecules have the potential to treat multiple neuromuscular and neurodegenerative
